Mergers + Acquisitions (M+A)

Mid-Atlantic Bio Angels (MABA), an angel investor group focused on early-stage life science companies, announced that Sisu Global Health was voted as "Best in Show" at one of MABA's 1st Pitch Life Science event, which took place at the Cira Center in Philadelphia on September 30, 2015.  Partner Stephen M. Goodman, a co-founder of MABA, served as one of five life science experts and investors on a panel at the bi-monthly event.  Sisu is a medical device developer with a pipeline of products designed to address challenges unique to emerging markets.  Hemafuse, the Company's first product, is a device designed to allow a care giver to reinfuse a bleeding patient’s own blood and could benefit 20 million cases in Africa ($600 million) each year.

According to Goodman, MABA was formed more than three years ago to provide a platform for pre-screened, promising life science companies to pitch to high net worth individuals who themselves have strong backgrounds in life sciences.  Because the founders of early stage companies are often unfamiliar with the concerns of investors, MABA organized its 1^stPitch Life Science initiative to provide an opportunity for a life science entrepreneur to “test market” the company’s pitch and business plan in front of an investor panel and a knowledgeable audience but without asking for money.  The presenters receive constructive feedback from the panel with the hope that they will utilize the feedback to make themselves more “investable”.  Several of the “Best in Show” winners at 1^stPitch have eventually qualified to seek funding from MABA itself,  “Sisu deserved its win,“ said Goodman.  "Where many companies fail to make a convincing case for selling into developing countries, Sisu’s management demonstrated a thoughtful, substantive approach based on the principals' years spent and relationships developed in the targeted nations. The simplicity and utility of the devices' design seem likely to make an impact in the targeted market. “